Assessing Benefit in Patients With Heart Failure and Reduced Ejection Fraction: Analysis of the VICTORIA Trial Using Novel Prognostic Risk Stratification
Journal of Cardiac Failure · 2025-08
DOI: 10.1016/j.cardfail.2025.07.024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cardiac Failure, 2025-08. Verfasst von Christopher M O'Connor und 17 weiteren Autor:innen. Beteiligte Einrichtung: Inova Schar Heart and Vascular, Falls Church, VA, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Bayer, Merck & Co Inc.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
BACKGROUND: Randomized trials remain the standard for evaluating novel therapies. Primary endpoint(s) risk heterogeneity and may dilute treatment efficacy. The 5-step Stratified Testing and Amalgamation Routine (5-STAR) methodology helps to address these limitations. We applied this methodology to the original VICTORIA (VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction) database and enriched it by relevant ancillary information. METHODS: Elastic net Cox regression and a conditional inference-tree tool blinded to treatment assignment partitioned the population into risk strata for endpoints based on baseline covariates strongly associated with outcomes. Core laboratory biomarkers and baseline electrocardiographic variables were available covariates. After unblinding, treatments were compared for the primary composite endpoint of cardiovascular death or heart failure hospitalization (HFH) within each risk stratum: stratum-level results were averaged for overall inference. RESULTS: The 5-STAR analysis revealed greater vericiguat efficacy pooled on the primary composite endpoint than the original VICTORIA analysis (5-STAR HR, 95% CI: 0.85, 0.77-0.94 vs 0.90, 0.82-0.98), and its components (5-STAR HR, 95% CI: cardiovascular death: 0.79, 0.67-0.93 vs 0.93, 0.81-1.06; HFH: 0.89, 0.79-1.00 vs 0.90, 0.81-1.00). Five biomarkers (GDF-15, NT-proBNP, albumin, blood urea nitrogen, and uric acid) determined the risk strata across the 3 endpoints. CONCLUSIONS: The 5-STAR methodology attenuates the dilution of treatment effects inherent in conventional prognostic risk heterogeneity. This retrospective analysis of VICTORIA revealed greater efficacy of vericiguat on the primary endpoint and its components. GDF-15 was consistently the strongest prognostic risk factor across the composite endpoint and its components.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Inova Schar Heart and Vascular, Falls Church, VA, USA.
- Canadian VIGOUR Centre, University of Alberta, Edmonton, Alberta, Canada.
- Merck & Co., Inc., Rahway, NJ, USA.
- Bayer AG, Basel, Switzerland.
- National Heart Centre Singapore and Duke-National University of Singapore, Singapore, Singapore.
- Division of Cardiology, Department of Internal Medicine, University Medicine Rostock, Rostock, Germany.
Förderung
- Bayer
- Merck & Co Inc
Zitieren
APA
O'Connor, C. M., Rathwell, S., Mehrotra, D. V., Corda, S., McMULLAN, C. J., Lam, C. S. P., Ezekowitz, J. A., Piekse, B., Hernandez, A. F., Anstrom, K. J., Mentz, R. J., Defilippi, C. R., Voors, A., Ponikowski, P., Butler, J., Westerhout, C. M., Armstrong, P. W., & VICTORIA Study Group (2025). Assessing Benefit in Patients With Heart Failure and Reduced Ejection Fraction: Analysis of the VICTORIA Trial Using Novel Prognostic Risk Stratification. Journal of Cardiac Failure. https://doi.org/10.1016/j.cardfail.2025.07.024
Vancouver
O'Connor CM, Rathwell S, Mehrotra DV, Corda S, McMULLAN CJ, Lam CSP, et al. Assessing Benefit in Patients With Heart Failure and Reduced Ejection Fraction: Analysis of the VICTORIA Trial Using Novel Prognostic Risk Stratification. Journal of Cardiac Failure. 2025. doi:10.1016/j.cardfail.2025.07.024
BibTeX
@article{OConnor2025,
author = {O'Connor, Christopher M and Rathwell, Sarah and Mehrotra, Devan V and Corda, Stefano and McMULLAN, Ciaran J and Lam, Carolyn S P and Ezekowitz, Justin A and Piekse, Burkert and Hernandez, Adrian F and Anstrom, Kevin J and Mentz, Robert J and Defilippi, Christopher R and Voors, Adriaan and Ponikowski, Piotr and Butler, Javed and Westerhout, Cynthia M and Armstrong, Paul W and VICTORIA Study Group, VICTORIA Study Group},
title = {Assessing Benefit in Patients With Heart Failure and Reduced Ejection Fraction: Analysis of the VICTORIA Trial Using Novel Prognostic Risk Stratification},
journal = {Journal of Cardiac Failure},
year = {2025},
doi = {10.1016/j.cardfail.2025.07.024}
}
EUVIMED